Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

clomiPRAMINE hydrochloride Capsules USP

Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during 18-month long term stability study.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-492-01 D-0377-2025
Class II · Moderate risk

Testosterone Cypionate Injection

cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.

Ongoing cGMP deviation Eugia US LLC NDC 55150-277-01 D-0363-2025
Class II · Moderate risk

Wegovy (semaglutide)

Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released.

Ongoing Temperature excursion Cardinal Health Inc. NDC 0169-4524-14 D-0393-2025
Class II · Moderate risk

Glycopyrrolate

Lack of Assurance of Sterility: Leaking/damaged syringes.

Ongoing Sterility / contamination Denver Solutions, LLC DBA Leiters Health NDC 71449-104-11 D-0370-2025
Class II · Moderate risk

Unisom

CGMP Deviations; detection of Nitrosamine Drug Substance-Related Impurities (NDSRI), N-nitroso-desmethyl-diphenhydramine (n-dph), above the FDA Recommended Intake Limit

Ongoing Nitrosamine impurity Chattem Inc D-0362-2025
Class II · Moderate risk

Duloxetine Delayed-Release Capsules

CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.

Ongoing Nitrosamine impurity Breckenridge Pharmaceutical, Inc. NDC 51991-747-10 D-0308-2025
Class II · Moderate risk

Voriconazole Tablets

cGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product.

Terminated cGMP deviation Amerisource Health Services LLC NDC 60687-294-21 D-0307-2025

Recalls by year